Enliven Therapeutics moves ELVN-001 closer to Phase 3 as CML drug competition intensifies
Find out how Enliven Therapeutics’ ELVN-001 data and FDA alignment could reshape chronic myeloid leukemia drug development.
Pharma & Biotech
Pharma & Biotech
Enliven Therapeutics moves closer to Phase 3 as ELVN-001 faces its real test
ELVN-001 has early CML promise and a long cash runway. Phase 3 execution now decides whether Enliven Therapeutics can justify the hype.